Presentation is loading. Please wait.

Presentation is loading. Please wait.

Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M

Published byFabian Lang Modified over 5 years ago

Similar presentations

Presentation on theme: "Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M"— Presentation transcript:

1 Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome 
Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W.M. van der Meer, MD, PhD, Anna Simon, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 128, Issue 6, Pages (December 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Rapid resolution of urticaria and arthritis on the first canakinumab injection. Pictures show urticarial rash in patients 1 and 2, arthritis of the left hand in patient 3 before canakinumab administration, and resolution of symptoms 4 days after injection. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Canakinumab treatment induces long-term suppression of systemic inflammation in patients with Schnitzler syndrome. C-reactive protein concentrations increased dramatically on cessation of anakinra and rapidly normalized after canakinumab administration (normal, <10 mg/L). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M"

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Defective B-cell memory in patients with Down syndrome Ruud H.J. Verstegen, MD, Gertjan J. Driessen, MD, Sophinus J.W. Bartol, BSc, Carel J.M. van Noesel,

Defective B-cell memory in patients with Down syndrome Ruud H.J. Verstegen, MD, Gertjan J. Driessen, MD, Sophinus J.W. Bartol, BSc, Carel J.M. van Noesel,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events  Keiichi Yamanaka, MD, PhD, Hitoshi.

“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events  Keiichi Yamanaka, MD, PhD, Hitoshi.
Alveolar nitric oxide and asthma control in mild untreated asthma

Alveolar nitric oxide and asthma control in mild untreated asthma
Doina M. Racila, MD, Joel N. Kline, MD, MSc 

Doina M. Racila, MD, Joel N. Kline, MD, MSc 
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Fatty acids, inflammation, and asthma

Fatty acids, inflammation, and asthma
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome  Heleen D. de Koning, MD, Mariëlle E. van.

Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome  Heleen D. de Koning, MD, Mariëlle E. van.
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Dennis K. Ledford, MD, Sally Wenzel, MD 

Dennis K. Ledford, MD, Sally Wenzel, MD 
David A. Khan, MD  Journal of Allergy and Clinical Immunology 

David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Desensitization to Chemotherapeutic Agents

Desensitization to Chemotherapeutic Agents
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Fatty acids, inflammation, and asthma

Fatty acids, inflammation, and asthma

Similar presentations

Ads by Google